3 results
Approved WMOCompleted
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
Approved WMOCompleted
To evaluate the effects on ovarian function with the NOMAC/E2 COC in a group of women aged 18-35 years.
Approved WMOCompleted
• To assess contraceptive efficacy, vaginal bleeding patterns (cycle control),general safety and acceptability of the NOMAC-E2 COC in a large group ofwomen aged 18-50 years.